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Abstract Background Knowledge of drug-related prob-
lems (DRPs) identified in the medication of home-dwelling
elderly patients with polypharmacy has been based predom-
inantly on medication reviews conducted in research settings
rather than in daily practice. Objective To evaluate the
prevalence of DRPs identified by means of a clinical medi-
cation review (CMR) and the implementation rate of proposed
interventions in a large group of older patients with
polypharmacy in the daily practice of community pharmacies.
Setting 318 Dutch community pharmacies. Method A cross-
sectional study based on CMR-data of 3807 older patients
(C65 years) with polypharmacy (C5 drugs) completed
between January and August 2012. Data were extracted from
community pharmacists’ databases and entailed: year of birth,
gender, dispensing data, number and nature of identified
DRPs, consultations performed, proposed and implemented
interventions. Main outcome measure Prevalence of DRPs,
drug classes involved in overtreatment and undertreatment,
and proposed and implemented interventions. Results A
median of two DRPs (interquartile range 1–4; mean 3.0) was
identified per patient. The DRP-categories overtreatment
(25.5 %) and undertreatment (15.9 %) were found most fre-
quently. 46.2 % of the proposed interventions to solve DRPs
were implemented as proposed, in 22.4 % of cases, the
intervention differed from the proposal. In 31.3 % of cases no
intervention was implemented. Conclusion By conducting a
CMR community pharmacists identified a median of two
DRPs inolder patientswithpolypharmacy.Overtreatment and
undertreatment accounted for 41.4 % of the DRPs identified.
In dealing with DRPs, pharmacists proposed a variety of
interventions of which the majority (69.9 %) was either
implemented or led to alternative interventions. A set of
explicit criteria should be applied during a CMR to solve and
prevent DRPs.
Keywords Clinical medication reviews  Community
pharmacists  Drug-related problems  Netherlands  Older
adults  Patient care  Pharmaceutical care
Impact of findings on practice
• Clinical medication reviews routinely conducted by
community pharmacists contribute to a reduction ofDRPs
in the medication of older patients with polypharmacy.
• The application of explicit criteria (STOPP/START or
the Amsterdam Tool) in a clinical medication review
may be a useful method to identify (potential) DRPs
frequently found in the medication of older patients
with polypharmacy.
Introduction
Conducting medication reviews is a method often recom-
mended to identify and solve drug-related problems
(DRPs) in order to optimise drug treatment and to improve
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patient health outcomes [1–3]. DRPs can be defined as
events involving drug treatment that are actually or
potentially harmful to a patient’s health or prevent patients
to optimally benefit from treatment [4]. The term medica-
tion review is used for a broad array of interventions, which
are aimed to identify and solve DRPs. A clinical medica-
tion review (CMR) entails a review involving communi-
cation with the patient while considering treatment in the
context of the patient’s underlying condition and symptoms
[2]. The advantage of patient involvement is the identifi-
cation of more DRPs and the possibility to identify DRPs
which are particularly relevant to the patient and therefore
should be tackled with priority [5–8]. The risk of DRPs
increases with age, number of diseases and number of
drugs prescribed [9, 10]. Older patients with polypharmacy
are most likely to benefit from a medication review [11, 12]
as they are more vulnerable to complications and admis-
sion to hospital caused by DRPs [9]. Knowledge of DRPs
identified in home-dwelling older patients with polyphar-
macy and their origin predominantly has been derived from
medication reviews in research settings rather than in daily
practice of community pharmacy. Medication reviews
conducted in research settings identified 2.5–10 DRPs in
older patients with polypharmacy [7, 13, 14]. Differences
in the number of identified DRPs can be explained by
variations in the target population, experience of the
pharmacist conducting the review, extent of patient
involvement, access to General Practitioner’s (GP) medical
records, and patient-related factors such as age, number of
diseases, number of drugs, and living conditions (e.g. res-
idential versus home dwelling) [15–17].
Knowledge of the type of DRPs in the elderly identified
by means of a CMR has been mainly obtained from studies
of 100 up to 400 patients. DRPs most frequently identified
relate to drug selection problems (27.8–42.0 %) [7, 13, 14],
over- and underdosing (10.8–30.0 %), and over-
(9.0–29 %) and undertreatment (3.0–27.9 %) [7, 13, 14,
18, 19]. However, data on DRPs identified by means of a
CMR in daily practice is scarce. A study on Australian
CMRs conducted by accredited community pharmacists
nationwide between 1998 and 2005 in daily practice
revealed on mean 4.6 DRPs per patient. DRPs most fre-
quently identified were drug selection problems (24.9 %),
toxicity, adverse reactions and side effects (19.7 %), and
undertreatment (15.7 %). Over- and underdosing com-
prised 8.9 % of the DRPs [17].
A limited number of studies has reported whether and
how proposals for interventions forthcoming from CMRs
were dealt with, using heterogeneous outcome measures
[14, 19–24]. Agreement of the prescriber with the proposal
was reported in two studies and amounted to 41.8 and
75.3 % respectively [19, 20]. Changes observed in clinical
or pharmacy records on the basis of CMRs were reported
as implementation rates between 17 and 85 % [14, 20–23].
However, as yet data on implementation rates in daily
practice are lacking.
In the Netherlands, community pharmacists started to
conduct CMRs in older patients with polypharmacy on a
large scale as part of the care contractually agreed with
health insurers. This enabled the implementation of pro-
posed interventions in daily practice and the current study
on DRPs. Standard health insurance is legally compulsory
for every person living or working in the Netherlands [25].
Dutch community pharmacies use computerised systems to
register dispensed medication which also enables registra-
tion of over-the-counter medication [26]. Most patients are
registered in a single pharmacy while shopping behaviour
(i.e. visiting more than one pharmacy) tends to be low [27].
When a patient visits another pharmacy and patient per-
mission is obtained, the patients’ main pharmacy is
informed about the dispensed medication and dosing
advices, electronically by using a secured connection or by
a fax message. Prescribers are also obliged to list the
indication when prescribing a drug that appears on a list of
23 selected drugs with a small therapeutic window, and to
actively inform pharmacists in the case of an abnormal
renal function [28]. This enables community pharmacists to
keep medication records complete and detect drug–drug
interactions among others. These Dutch requirements are
quite unique in comparison with pharmacy practice in other
countries [27].
Aim of the study
The present study aimed to investigate the number of DRPs
in the elderly with polypharmacy identified by means of a
CMR in daily practice of community pharmacy and the
implementation rate of the proposed interventions.
Ethical approval
Since anonymised data extracted from the community
pharmacists’ databases were used, ethical approval was not
required according to Dutch legislation.
Method
Design and setting
A cross-sectional study was carried out based on CMRs in
older patients with polypharmacy completed between
January and August 2012. Data were acquired from all 318
Dutch community pharmacies affiliated to Nederlandse
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Service Apotheek Beheer (16 % of all community phar-
macies), a franchise organisation of independent commu-
nity pharmacies, located across the Netherlands. Patient
characteristics, prevalence of identified DRPs, and pro-
posed and implemented interventions have been registered
in a database using the Service Apotheek Medication
Review Tool (SAMRT) in NControl, a collection of web
applications supporting the process of pharmaceutical care.
Study population
In 2012 eight Dutch health insurance companies (combined
market share[85 %) contracted CMRs to be conducted by
community pharmacists though imposing different patient
criteria for reimbursement. For example, one insurer
excluded patients with multidose drug dispensing systems
(MDD) from CMR. In MDD, medication are packaged and
ordered in separate compartments for each dose occasion
and labelled with patient data, date and time of intended
intake and drug contents. Other insurers only reimbursed
CMRs for patients using specific drug classes such as drugs
for COPD or specific combinations of cardiovascular
drugs.
However, the CMRs of all patients could be registered
in the SAMRT database. From this database, the study
population for the current study was composed, consisting
of patients aged 65 years or older with polypharmacy.
Polypharmacy is defined as the use of at least five drugs
indicated for the treatment of a chronic disease at the
anatomical therapeutic chemical (ATC)-5 level in the past
four months. In case of preparations for sensory organs,
only drugs intended for long-term use were included (ATC-
class S01E,F,G). Anti-infectives (ATC-class J, G01,
S01A,C, S02A,C) are intended for short-term use and
therefore have been excluded. Drugs less likely to cause
relevant DRPs, such as dermatologicals (ATC-class D) and
topical products (ATC-class M02), were also excluded for
the calculation of the total number of drugs.
Clinical medication review
CMRs were conducted by community pharmacists who
completed a medication review training accredited by the
Royal Dutch Pharmacists Association. Pharmacists fol-
lowed a method that evolved into the STRIP method [29].
Each CMR started with a semi-structured interview with
the patient. In this interview, the aim and use of the
patients’ medication were discussed as well as any DRP
experienced or perceived by the patient. In conducting a
CMR pharmacists were supported by the SAMRT. Dif-
ferent pharmacists may have been involved in conducting
the CMRs, if multiple pharmacists were employed in a
pharmacy. The medication review tool guides the
pharmacist through the medication history of the patient to
identify possible DRPs. Proposed interventions were dis-
cussed with the prescriber, unless the intervention was not
regarding a change of medication i.e. repeating an inhaler
instruction or creating a dosing schedule. Final proposals to
be implemented were discussed with the patient by the
pharmacist. Furthermore, SAMRT served as a registration
tool to CMR proceedings including a summary of the
patient interview, registration of diseases (International
Classification for Primary Care, ICPC code), DRPs iden-
tified, whether the prescriber and/or patient was consulted
to solve the DRP and proposed and implemented
interventions.
Data collection
Data of patients of 65 years and older with polypharmacy
were extracted from the community pharmacists’ databases
(pharmacy information and administration system and
SAMRT). Data entailed: year of birth, gender, dispensing
data, number and nature of identified DRPs, consultations
performed, proposed interventions and those implemented.
Outcome measures and data analysis
Descriptive analyses were performed on anonymised data
of the outcome measures using statistical software (SPSS
version 20.0). Characteristics have been presented as
number and mean [with standard deviation (SD)]. For
variables that were not normally distributed, both the
median [with interquartile range (IQR)] and mean is
reported in order to be able to compare results with the
existing literature. Percentages of drug classes involved in
the two largest DRP categories were calculated by dividing
the number of DRPs involving the drug class on the total
number of DRPs in that category.
Results
Patient characteristics
3807 CMRs were conducted in older patients with
polypharmacy across 258 of 318 pharmacies. The partici-
pating older adults had a mean age of 78 years; 57.9 %
were female. Patients used a median of nine drugs (IQR
7–11; mean 9.54) for the treatment of a chronic disease
(see Table 1). No patient received more than one CMR.
Number of DRPs and DRP prevalence
Table 2 lists the number of the various DRPs that were
identified. In total, 11,419 DRPs were found in 3807
48 Int J Clin Pharm (2016) 38:46–53
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patients. A median of two (IQR 1–4) DRPs was found per
patient (mean: 3.0). Overtreatment (25.5 %) and
undertreatment (15.9 %) were the most common DRPs.
Other DRP-categories each contributed 5.0–8.5 % to the
total number of DRPs reported. Inappropriate dosage form
was the least common DRP (0.8 %).
Drug classes involved in overtreatment
and undertreatment
Drug classes involved in the DRP categories overtreatment
and undertreatment have been listed in Table 3. Drug
classes most frequently involved in overtreatment are drugs
for peptic ulcer and gastro-oesophageal reflux disease
(GORD, 10.2 %), antithrombotic agents (6.7 %) and lipid
modifying agents (5.2 %).
The majority of the drugs for peptic ulcer and GORD
involved in overtreatment were proton-pump inhibitors
[PPI, (n = 281, 94.9 %)]. PPIs were classified as
overtreatment because there was no clear indication or
gastroprotective medication was no longer needed since a
non-steroidal anti-inflammatory drug (incl. acetylsalicylic
acid) or selective serotonin reuptake inhibitor was stopped
previously. Vitamin K antagonists (n = 47) were regarded
as overtreatment because the indication was unclear or
unknown to the patient and pharmacist. However, after
consultation with the prescriber, these drugs frequently
turned out to be indicated. In most cases clopidogrel was
registered as overtreatment (n = 38), mainly because the
patient had used it longer than 1 year and treatment could
be discontinued according to the current medical guide-
lines. Rosuvastatin contributed 50.3 % (n = 77) to the
group of lipid modifying agents. Lipid modifying agents
and antithrombotic agents were also involved in
undertreatment, 2.9 and 2.6 % respectively, followed by
vitamin A and/or D (2.5 %).
Interventions
Proposed interventions have been listed in Table 4. Stop-
ping to use a drug was suggested most frequently (19.6 %),
second most suggested was monitoring of the patient
(18.4 %), e.g. measuring of the blood pressure or per-
forming a blood test. 46.2 % of the interventions were
implemented as proposed. In 22.4 % of the cases, the
intervention effectuated differed from the proposal and in
31.3 % of the cases, no intervention was performed. Rea-
sons for not implementing an intervention included a
rejection by the prescriber (27.5 %) or patient (11.9 %);
and correction of the DRP in the time between the patient
interview and the consultation with the physician (mostly a
GP) or patient (13.1 %). Some interventions were not
implemented immediately, but instead the patient was
monitored to decide whether the intervention was indicated
at a later moment (26.2 %). An overview of all interven-
tions effectuated can be found in Table 5.
Discussion
The objective of this study was to investigate the number
and nature of DRPs identified by means of a community
pharmacist-conducted CMR in 3807 older patients with
polypharmacy in daily practice. The implementation rate of
interventions proposed to solve DRP was also investigated.






Mean (SD) 78 (7.68)
Range 65–102
Number of chronically used drugs
Median (IQR) 9 (7–11)
Mean (SD) 9.54 (3.40)
Range 5–27
Number of DRPs
Median (IQR) 2 (1–4)
Mean (SD) 3.00 (2.26)
Range 1–26
SD standard deviation, IQR interquartile range
Table 2 Number of DRPs per category
DRP categories n %
Overtreatment 2915 25.5
Undertreatment 1814 15.9
Drug not effective 975 8.5
Contra-indication 971 8.5
Side effect 923 8.1
Difficulty using dosage form 756 6.6
Interaction 664 5.8
Non adherence 645 5.6
Dose too low 622 5.4
Dose too high 568 5.0
Inappropriate dosage form 96 0.8
Miscellaneous problema 470 4.1
Total DRPs 11,419 100
a Besides drug-related problems, the category ‘miscellaneous prob-
lem’ also contained non-drug-related problems, for example, lifestyle
advice given such as smoking cessation
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In older patients with polypharmacy whose medication
was evaluated by means of a CMR three DRPs were
identified on mean. This number is on the lower end of the
range of 2.5–10 DRPs found for these patients in research
settings [7, 13, 14] and comparable with the 4.6 DRPs
previously found in daily practice [17]. However, com-
parison is problematic as DRPs are not normally
distributed, but skewed to the right. Future studies should
report median and IQR to allow better inter-study com-
parisons of the number of DRPs.
Overtreatment (25 %) was the most frequently identified
DRP. The prevalence of overtreatment was within the
range found in research settings (15.7–29 %) [7, 13, 14,
18]. Other studies also showed that cessation of medication
Table 3 Drug classes involved in DRP categories overtreatment and undertreatment
n Percentage (%)
Drug classes involved in overtreatment
A02B Drugs for peptic ulcer and GORD 296 10.2
B01A Antithrombotic agents 195 6.7
C10A Lipid modifying agents 153 5.2
A06A Drugs for constipation 103 3.5
N05B Anxiolytics 83 2.8
N05C Hypnotics and sedatives 75 2.6
N06A Antidepressants 71 2.4
C03C High-ceiling diuretics 66 2.3
C07A Beta blocking agents 60 2.1
N02B Other analgesics and antipyretics 60 2.1
Drug classes involved in undertreatment
C10A Lipid modifying agents 53 2.9
B01A Antithrombotic agents 48 2.6
A11C Vitamin A and/or D 46 2.5
A12A Calcium 26 1.4
A10B Blood glucose lowering drugs, excl. insulin 23 1.3
A02B Drugs for peptic ulcer and GORD 17 0.9
C01D Vasodilators used in cardiac diseases 15 0.8
M05B Drugs affecting bone structure and mineralisation 15 0.8
C09A ACE inhibitors 14 0.8
C07A Beta blocking agents 11 0.6
Percentage given is the percentage of a drug class reported in the DRP category. GORD gastro-oesophageal reflux disease
Table 4 Prevalence and type of proposed interventions after identification of the DRP by pharmacists
Number Percentage (%) Implemented (%) Other intervention (%) No intervention (%)
Stop drug 2238 19.6 46.6 21.4 32.0
Provide monitoring 2099 18.4 52.8 23.1 24.1
Adjust dose 1684 14.7 43.3 25.1 31.6
Add drug 1601 14.0 36.3 27.4 36.3
Switch drug 1307 11.5 38.5 26.0 35.5
Provide education 1225 10.7 67.9 12.3 19.8
Synchronise medication 304 2.7 82.6 12.5 4.9
Switch dose form 176 1.5 60.2 24.4 15.4
Other 766 6.7 15.5 21.5 63.0
Total 11,419 100.0 46.2a 22.4a 31.3a
a These percentages were calculated based on the known outcomes (11,400) as a proportion of the total interventions (11,419). 0.2 % of the
interventions (n = 19) was not attributed to a specific category
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was the most common recommendation following a CMR.
In this respect, it should be noted that the past decade
attention for the deprescribing of superfluous drug has
increased [30]. Undertreatment (16 %) was the second
most frequently identified DRP. This percentage is similar
to that found in a previous study on CMRs in daily practice
(15.7 %) [17] and also within the range obtained in
research settings (3.0–27.9 %) [7, 13, 14, 18, 19].
Overtreatment and undertreatment accounted for 41.4 % of
the DRPs identified. This implicates that explicit criteria
developed for the detection of potentially inappropriate
drugs and potentially omitted beneficial drugs, such as the
STOPP/START criteria may be useful during a CMR as a
tool to systematically screen the medication of the patient.
However, rather than overtreatment and undertreatment, a
larger part of DRPs concerned other DRPs (i.e. drug not
effective, side effect, difficulty using dosage form). For
additional support of the CMR process, explicit criteria
addressing these DRPs may be useful, for example by
using the recently developed Amsterdam Tool [31].
Drugs for peptic ulcer and GORD, antithrombotic agents
and lipid modifying agents were most frequently involved
in overtreatment. It is known that in some cases, drugs for
peptic ulcer and GORD are used longer than indicated for
GORD [32, 33] or gastroprotection. The unnecessary use of
gastroprotective medication in some cases may be
explained by the continuation of gastroprotective medica-
tion after the gastric problem enhancing drug was discon-
tinued. Lipid modifying agents and antithrombotic agents
were also frequently involved in overtreatment, as well as
undertreatment. This could be explained by the fact that
some patients with an indication are not treated, while
others may receive a more potent drug than necessary (e.g.
rosuvastatin while simvastatin has not been tried first).
Drug classes used more often may have resulted in a higher
percentage in a DRP-category. However, this still provides
important information. By giving more attention to these
drug classes, which caused a large number of DRPs, the
number of DRPs may decrease.
Nearly half (46.2 %) of all pharmacist-proposed inter-
ventions were implemented as proposed. Furthermore, in
an additional 23.7 % of cases, DRPs were dealt with in a
manner different from the adjustment initially proposed.
Apparently, discussion with GPs and patients in the CMR
process influenced the choice of interventions and resulted
in different adjustments. In research settings, implementa-
tion rates between 17 and 85 % were found [14, 19–24]
and implementation rates were found to be generally higher
when pharmacists had more clinical experience, had access
to GP medical records and when a patient interview was
part of the review process [34]. Higher implementation
rates have also been found in studies focussing on selected
DRPs [19] or in studies in which only a limited number of
interventions were proposed [22]. Some of these factors
may have had an effect on the implementation rate in the
present study. The pharmacists in the present study pro-
posed many interventions on a wide range of DRPs. This
may have had a negative effect on the implementation rate
whereas the patient interview may have had a positive
effect. Although community pharmacists were specifically
trained to conduct CMRs, it is likely that some community
pharmacists still had limited experience in conducting
CMRs, largely because in the Netherlands routinely con-
ducted CMR were only reimbursed from 2012 on a larger
scale. Finally, for effectively addressing DRPs, close
cooperation with the GP seems important [34]. Unfortu-
nately, there were no data providing information to what
extent this cooperation was practised.
To appreciate the findings of the present study some
points that may have affected the results must be addres-
sed. First, the SAMRT has been designed to support
pharmacists in conducting CMR in a structured manner on
a routine basis, not as a registration system for research
purposes. This might have resulted in a registration bias,
due to variability in the registration of DRPs which in turn
would have affected the findings on number and nature of
DRPs and implementation rates. However, arguing against
this potential bias as well as being a strength of this study,
is that all pharmacists completed the same training and
used the same SAMRT tool. Second, requirements for
CMR reimbursement of pharmacists by the health insurers
involved led to some heterogeneity in the patient popula-
tion. Regarding the exclusion of patients using a MDD: this
might have led to a lower number of DRPs, because
patients using MDD are known to have more DRPs [35].
Some insurers only reimburse CMRs for patients using
specific drug classes such as drugs for COPD or specific
combinations of cardiovascular drugs, which might have
influenced the number of DRPs. Pharmacists may also have
selected those patients who they assumed to benefit the
Table 5 Distribution of interventions implemented after identifica-
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most, i.e. are more likely to suffer from DRPs, which might
have increased the number of DRPs. On the other hand,
other pharmacists may have approached all eligible
patients until they met the number of CMRs they con-
tractually agreed to conduct, which might have influenced
the number of DRPs as the selection was more random, i.e.
also patients with less DRPs. To what extent these issues
affected the findings overall, cannot be determined. Third,
the experience of the pharmacists has not been taken into
account. Although all pharmacists were trained to conduct
CMRs in the same fashion, this may have influenced the
number of DRPs identified and the percentage of inter-
ventions implemented. Nevertheless, since this was a cross-
sectional sample, it may be regarded as representative of
trained community pharmacists with varying experience
with conducting CMRs.
Conclusion
In the present study, conducted in daily practice, commu-
nity pharmacists identified on mean three DRPs as the
result of a CMR in older patients with polypharmacy. This
number is similar to that of previous studies predominantly
conducted in a research setting. Overtreatment and
undertreatment accounted for less than half of the DRPs
identified (41.4 %). More attention for drug classes regu-
larly involved with DRPs may further decrease the number
of DRPs. In dealing with DRPs, pharmacists proposed a
variety of interventions of which the majority (69.9 %) was
either implemented or led to alternative interventions. The
application of explicit criteria (STOPP/START or the
Amsterdam Tool) in a CMR may be useful in addressing
and preventing DRPs frequently found in the medication of
older patients with polypharmacy.
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